1137 related articles for article (PubMed ID: 32708317)
41. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
42. Osteocyte-driven bone remodeling.
Bellido T
Calcif Tissue Int; 2014 Jan; 94(1):25-34. PubMed ID: 24002178
[TBL] [Abstract][Full Text] [Related]
43. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
44. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
46. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
47. Aminothiazoles inhibit osteoclastogenesis and PGE
Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
[TBL] [Abstract][Full Text] [Related]
48. A Novel Rhein Derivative Modulates Bone Formation and Resorption and Ameliorates Estrogen-Dependent Bone Loss.
Jiang M; Wang T; Yan X; Liu Z; Yan Y; Yang K; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Xi X; Yang C; Deng L
J Bone Miner Res; 2019 Feb; 34(2):361-374. PubMed ID: 30320929
[TBL] [Abstract][Full Text] [Related]
49. RANK, RANKL and osteoprotegerin in arthritic bone loss.
Bezerra MC; Carvalho JF; Prokopowitsch AS; Pereira RM
Braz J Med Biol Res; 2005 Feb; 38(2):161-70. PubMed ID: 15785827
[TBL] [Abstract][Full Text] [Related]
50. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn's patients via bone formation and bone resorption.
Blaschke M; Koepp R; Cortis J; Komrakova M; Schieker M; Hempel U; Siggelkow H
Adv Clin Exp Med; 2018 Jan; 27(1):45-56. PubMed ID: 29521042
[TBL] [Abstract][Full Text] [Related]
51. The osteocyte and its osteoclastogenic potential.
Marahleh A; Kitaura H; Ohori F; Noguchi T; Mizoguchi I
Front Endocrinol (Lausanne); 2023; 14():1121727. PubMed ID: 37293482
[TBL] [Abstract][Full Text] [Related]
52. The pathophysiology of immunoporosis: innovative therapeutic targets.
Ferbebouh M; Vallières F; Benderdour M; Fernandes J
Inflamm Res; 2021 Aug; 70(8):859-875. PubMed ID: 34272579
[TBL] [Abstract][Full Text] [Related]
53. Osteocytes and Paget's Disease of Bone.
Tenshin H; Delgado-Calle J; Windle JJ; Roodman GD; Chirgwin JM; Kurihara N
Curr Osteoporos Rep; 2024 Apr; 22(2):266-272. PubMed ID: 38457001
[TBL] [Abstract][Full Text] [Related]
54. Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte.
Wang T; Yu X; He C
Curr Drug Targets; 2019; 20(1):1-15. PubMed ID: 29618305
[TBL] [Abstract][Full Text] [Related]
55. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro.
Al-Dujaili SA; Lau E; Al-Dujaili H; Tsang K; Guenther A; You L
J Cell Biochem; 2011 Sep; 112(9):2412-23. PubMed ID: 21538477
[TBL] [Abstract][Full Text] [Related]
56. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin.
Andreev D; Liu M; Weidner D; Kachler K; Faas M; Grüneboom A; Schlötzer-Schrehardt U; Muñoz LE; Steffen U; Grötsch B; Killy B; Krönke G; Luebke AM; Niemeier A; Wehrhan F; Lang R; Schett G; Bozec A
J Clin Invest; 2020 Sep; 130(9):4811-4830. PubMed ID: 32773408
[TBL] [Abstract][Full Text] [Related]
57. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
[TBL] [Abstract][Full Text] [Related]
58. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue.
Ogasawara T; Yoshimine Y; Kiyoshima T; Kobayashi I; Matsuo K; Akamine A; Sakai H
J Periodontal Res; 2004 Feb; 39(1):42-9. PubMed ID: 14687227
[TBL] [Abstract][Full Text] [Related]
59. The role of cytokines in inflammatory bone loss.
Souza PP; Lerner UH
Immunol Invest; 2013; 42(7):555-622. PubMed ID: 24004059
[TBL] [Abstract][Full Text] [Related]
60. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
